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Major histocompatibility complex (MHC) multimers are essential tools in T cell immu-
nomonitoring, which are employed both in basic and clinical research, as well as for 
assessing clinical samples during therapy. The generation of MHC monomers loaded with 
synthetic peptides is an elaborate and time-consuming process. It would be beneficial to 
assess the quality of these monomers prior to downstream applications. In this technical 
note, we describe a novel flow cytometry-based, cell-free, quick, and robust assay to 
check the quality of MHC monomers directly after refolding or after long-term storage.
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INtRodUCtIoN
Heterotrimeric major histocompatibility complex (MHC) class I molecules consist of a polymorphic 
heavy chain, an invariant β2-microglobulin light chain and an 8–10 amino acid-long peptide located 
in the binding groove formed by the heavy and light chains (1, 2). T cell receptors (TCRs) expressed 
at the cell surface of CD8+ T lymphocytes interact very specifically with both their cognate peptide 
and with the MHC class I, forming the basis of MHC-restriction and antigen-specific T-cell immune 
response (3).
The peptide–MHC multimer technology makes use of this highly specific interaction and has 
evolved as an essential tool for monitoring antigen-specific CD8+ T cells (4–9). Recombinant 
peptide–MHC monomers (monomers) can also be immobilized as artificial antigen presenters to 
stimulate and expand peptide-specific T cells (10).
The conventional production of monomers is a multi-step process, which involves in vitro refold-
ing of the recombinant heavy chain together with β2-microglobulin and the peptide of interest, 
followed by BirA-dependent biotinylation (7, 11). Monomers can then be multimerized using 
fluorochrome-coupled streptavidin. Meanwhile, a number of commercial suppliers propose vari-
ous formats of MHC multimers and customized products for specific needs. While such reagents 
are generally of high-quality, they are expensive. Thus, many laboratories engaged in large-scale 
monitoring studies prefer in-house production of monomers, which is, however, labor intensive. 
For high-throughput generation of small quantities of monomers, the UV-based peptide exchange 
method is preferred (12).
Functionality of monomers and multimers, i.e., specific binding to cognate TCRs, depends on the 
quality and stability of the refolded complex and its appropriate biotinylation and multimerization. 
tABLe 1 | description of major histocompatibility complex (MhC) monomers and peptides used in this study.
MhC Peptide code Monomer code Peptide sequence source protein
HLA-A*02:01 A*02-BRLF1 HLA-A*02-BRLF1 YVLDHLIVV Epstein–Barr virus, BRLF1 protein
A*02-MelanA HLA-A*02-MelanA ELAGIGILTV Human, MelanA/MART-1 (modified)
HLA-B*07:02 B*07-EBNA3 HLA-B*07-EBNA3 RPPIFIRRL Epstein–Barr virus, EBNA3 protein
HLA-B*08:01 B*08-EBNA3 HLA-B*08-EBNA3 FLRGRAYGL Epstein–Barr virus, EBNA3 protein
MhC Peptide code Monomer code Peptide sequence description
HLA-A*02:01 A*02-UV HLA-A*02-UV KILGFVFJV UV-sensitive peptide
HLA-B*07:02 B*07-UV HLA-B*07-UV AARGJTLAM UV-sensitive peptide
HLA-B*08:01 B*08-UV HLA-B*08-UV FLRGRAJGL UV-sensitive peptide
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Issues that could lead to low-quality monomers/multimers 
include protein precipitation or aggregation during the in vitro 
refolding, use of low-affinity or unstable peptides, excess of free 
biotin, suboptimal biotinylation due to poor enzymatic activity or 
to cleavage of BirA site by contaminating proteases, poor quality 
of chromatographic purification of complexes, and incomplete 
UV-exchange (12). Basic quality control of MHC monomers can 
be performed by SDS/PAGE-mediated resolution or by liquid 
chromatography. Both methods can be used to check for the 
amount and quality of the individual constituents of the MHC 
complex (11, 13), but are of low throughput. Currently, the only 
high-throughput method available to assess the integrity of a 
monomer is an ELISA for the detection of β2-microglobulin (12). 
None of these methods can fully report whether the monomers 
still maintain a functional conformation, which is crucial for their 
functionality. In this technical note, we describe a flow cytometry-
based, novel, quick, high-throughput, and cost-effective assay to 
assess the quality and integrity of MHC monomers.
MAteRIALs ANd Methods
Antibodies
The following anti-MHC monoclonal antibodies (mAbs) were pro-
duced and purified in-house from hybridoma cultures. W6/32 and 
BB7.2 hybridomas were purchased from the European Collection 
of Authenticated Cell Cultures (ECACC) and the American 
Type Culture Collection (ATCC), respectively. The B1.23.2 
hybridoma was a kind gift from Dr. Bernard Malissen. The HC10 
and HCA2 hybridomas were a kind gift from Dr. Hidde Ploegh. 
The antibodies were used at the indicated pre-tested concentra-
tions: W6/32 (IgG2a, 1 µg/mL) (14), BB7.2 (IgG2b, 0.1 µg/mL) 
(15), B1.23.2 (IgG2b, 0.7 µg/mL) (16), HC10 (IgG2a, 0.6 µg/mL), 
and HCA2 (IgG1, 0.5  µg/mL). Both HC10 and HCA2 mAbs 
recognize linear HLA-class I epitopes, and, therefore, bind to 
free HLA-heavy chains (17–21). As respective isotype-matched 
negative controls, irrelevant antibodies IgG1 (clone MOPC21), 
IgG2a (mouse anti-trinitrophenol, clone G155-178), and IgG2b 
(mouse anti-H2-Kb, clone Y-3), were used.
MhC Monomers, UV-exchange, and 
Multimers
Peptides were synthesized in-house using an automated peptide 
synthesizer 433A (Applied Biosystems, Foster City, CA, USA) (22) 
and diluted at 10 mg/mL in 100% DMSO immediately before use. 
MHC–peptide monomers were generated by the conventional 
refolding method as described before: recombinant HLA heavy 
chains, light chain (β2-microglobulin), and the peptide of interest 
were refolded, biotinylated, and purified by FPLC (7). To gener-
ate non-biotinylated monomers, the biotinylation step was left 
out of the process. The concentration of the resulting monomers 
was determined by Bradford assay and reagents were aliquoted 
and frozen (−80°C) at 2 mg/mL concentration. Multimers were 
generated by incubating the monomers with streptavidin-PE or 
streptavidin-APC (Thermo Fisher Scientific) at a final 4:1 M ratio 
(7), aliquoted and frozen (−80°C) in the presence of glycerol and 
human serum albumin (23). The method for generation of mono-
mers by UV-exchange has been described previously (8, 12). In 
short, equal volume of UV-sensitive monomer (200 µg/mL in PBS 
containing 2  mM EDTA) and of replacement peptide solution 
(400 µg/mL in PBS with 2 mM EDTA) were mixed together and 
incubated for 1 h under UV-light (366 nm) in a 96-well micro-
plate (Greiner Bio-one GmbH, Frickenhausen, Germany) using 
a maximum volume of 130 µL per well. After UV-exchange, the 
plate was centrifuged at 3,300 g for 5 min at room temperature 
and 100 µL supernatant was collected from each well. Assuming 
a yield of 50%, the UV-exchanged monomer had a concentration 
of 50 µg/mL and was used directly for the bead assay or to gener-
ate multimers. When UV-exchange was performed without the 
replacement peptide, an equal volume of PBS containing 2 mM 
EDTA/DMSO was used instead. The peptides and monomers 
used in this study are listed in Table 1.
Bead Assay
A step-by-step workflow of the assay is shown in Figure  1. 
First, a 0.1  µg/mL MHC monomer solution was prepared in 
PBS. Streptavidin-coated microspheres (Cat. No. CP01N, Bangs 
Laboratories Inc., IN, USA), hereafter referred to as beads, at a 
concentration of 100,000 beads/μL, were washed twice (1,300 g, 
5 min, 4°C) in at least 10 times volume of PBS and resuspended in 
100 µL FACS buffer/100,000 beads [FACS buffer: PBS (in-house 
preparation) containing 0.02% sodium azide, 2 mM EDTA (Roth, 
Karlsruhe, Germany), and 2% heat-inactivated FCS]. The mono-
mer solution was then mixed with an equal volume of the bead 
solution and incubated at 4°C for 30 min. A single test, therefore, 
contained 100,000 beads in a 0.05 µg/mL (10 ng) monomer solu-
tion (optimized by titration, see Figure 2). The mixture was then 
FIGURe 1 | Workflow of the bead-based assay for controlling the quality of major histocompatibility complex-monomers: the five steps and the 
three assay conditions tested (i)–(iii) are shown. Details are given in the Section “Materials and Methods.”
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washed twice with 10 times the volume using FACS buffer by 
centrifuging (1,300 g, 5 min, 4°C). A total of 100,000 monomer-
loaded beads per test were distributed in a 96-well round-bottom 
plate and were centrifuged. The beads were then incubated with 
anti-MHC mAbs or relevant isotype control mAbs in a final 
volume of 50 µL/test for 30 min at 4°C, washed twice with 200 µL 
FACS buffer/test, and then stained with the secondary antibody 
(goat anti-mouse PE; Jackson ImmunoResearch, PA, USA) for 
30 min at 4°C. Finally, the beads were washed twice with FACS 
buffer, resuspended in 200 µL FACS buffer, and the PE fluores-
cence was measured on an LSR-Fortessa SORP (BD).
Acid treatment of MhC Monomers
Monomers produced by the conventional refolding method were 
bound onto the beads and were then denatured by treatment 
with an acid buffer. One million beads were incubated for 90 s 
in 1 mL acid buffer (0.3 M glycine HCl, 1% BSA in sterile water, 
pH 2.3) on ice, followed by one wash with 10 times volume PBS 
(24). Thereafter, the beads were washed twice using PBS and were 
stained as described above.
Multimer staining of PBMCs
To confirm MHC multimer functionality, we used PBMCs from 
HLA-A*02(+) donors 1, 3, and 4 obtained through venipunc-
ture as buffy coats and from donor 2 obtained twice (2a and 
2b) through leukapheresis (Center for Clinical Transfusion 
Medicine GmbH of the University Hospital in Tuebingen) 
after informed consent. PBMCs were isolated and stored in 
liquid nitrogen until use, as described before (4). Cryopreserved 
PBMCs were thawed and stained essentially following the CIP 
protocol (http://www.cimt.eu/workgroups/cip) (4). Cells were 
labeled with CD4 FITC (clone HP2/6, in-house production), 
CD8 PE-Cy7 (clone SFCI21-Thy2D3, Beckman Coulter), Aqua 
Live/Dead (Thermo Fisher Scientific), and multimers (PE- or 
APC-labeled).
data Acquisition and Analysis
Within 24 h after staining and fixation [FACS buffer containing 
1% formaldehyde (36% w/v; Sigma-Aldrich)], the cells and beads 
(not fixed) were acquired on an LSR-Fortessa SORP cytometer 
(BD Biosciences, Heidelberg, Germany) operated through the 
BD FACSDiva™ software (version 6.1.2). Spectral overlap was 
compensated using AbC and ArC beads (both from Thermo 
Fisher Scientific). Ten thousand beads or 1  ×  106  cells were 
acquired per test. The resulting data were saved as FCS 3.0 files 
and subsequently analyzed using FlowJo Mac version 9.7.5 or 
Windows version V10 (FlowJo LLC, Ashland, OR, USA).
Gating strategy and Analysis
PBMCs were serially gated following the hierarchy: time param-
eter histogram: cells that were non-linearly acquired over time 
were “gated out.” FSC-A vs. FSC-H dot plot: gate on singlets. 
FSC-A vs. Aqua Live/Dead dot plot: gate on living cells. FSC-A 
vs. SSC-A dot plot: gate on lymphocytes. CD8 PE-Cy7 vs. CD4 
FITC dot plot: gate on CD4(−) cells. CD8 PE-Cy7 vs. multimer 
(PE/APC): quadrant gate to determine CD8(+) multimer(+) cells 
(see example of a full analysis in Figure S2 in Supplementary 
Material). Beads were gated from the FSC-A vs. SSC-A plot, and 
the PE fluorescence was assessed on histogram plots. Respective 
median fluorescence index (MFI) values are shown in the figures. 
FIGURe 2 | Assessment of major histocompatibility complex (MhC) monomer biotinylation. (A) We titrated the biotinylated and non-biotinylated 
monomers (0.00005–5 µg/mL) on the beads and stained them with anti-MHC and relevant isotype control monoclonal antibodies. The complexes were 
subsequently detected using a PE-labeled secondary antibody. Specific fluorescence indices of the PE signal are plotted. (B) Histograms showing the binding of 
the respective anti-MHC antibodies to 0.05 µg/mL of the indicated biotinylated and non-biotinylated monomers. Representative data from one of two experiments 
are shown in (A,B).
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For Figure 2, the specific fluorescence index (SFI) was calculated 
as the ratio of MFI of the specific antibody to the MFI of the 
isotype control antibody.
ResULts
Principle of the Assay
The bead-based assay can be used to test two aspects of the MHC 
monomer integrity, i.e., whether the monomer has been bioti-
nylated and whether the monomer has refolded properly with 
the peptide. Binding of the monomers to the streptavidin-coated 
beads indicates their biotinylation. Recognition of an MHC 
monomer by the three mAbs W6/32, BB7.2, and B1.23.2 should 
reveal an intact complex (14–16), while the binding of HCA2 
and HC10 mAbs indicates an aberration in the heterotrimeric 
structure of the monomer (17–21).
Non-Biotinylated Monomers do Not Bind 
to the Beads
In order to test whether our assay can differentiate between 
non-biotinylated and biotinylated monomers, we generated 
non-biotinylated HLA-A*02, -B*07, and -B*08 monomers and 
compared their binding to the beads alongside their respective 
biotinylated monomers. At high monomer concentrations (0.5 
and 5  µg/mL), we observed some unspecific binding of the 
non-biotinylated monomers and, therefore, titrated down the 
FIGURe 3 | detection of denatured major histocompatibility complex (MhC) monomers. Beads were loaded with monomers, treated with an acidic buffer 
or with PBS (control), and then stained with the indicated anti-MHC monoclonal antibodies and relevant isotype controls, followed by detection with a PE-labeled 
secondary antibody. Representative histograms of PE fluorescences from one of two experiments are shown.
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amount of monomer on the beads. At monomer concentra-
tions of 0.05  µg/mL, binding of all three non-biotinylated 
monomers was minimal while all their biotinylated counterparts 
showed consequent binding as revealed by two specific mAbs 
(Figure 2A). Hence, this concentration was chosen for the next 
experiments. We further tested the binding of these monomers 
in their biotinylated and non-biotinylated forms to confirm that 
our assay can indeed differentiate them (Figure 2B; Figure S1 in 
Supplementary Material). As control, PBMCs were stained with 
multimers generated from the biotinylated and non-biotinylated 
monomers and as expected, only the biotinylated ones could 
detect HLA-A*02-BRLF1 (Figure S2 in Supplementary Material) 
and HLA-B*07-EBNA3 (data not shown)-binding CD8+ cells.
the Assay Can detect the dissociation  
of the MhC Complex
If the complex formed by the MHC heavy chain, β2 microglobu-
lin, and peptide happens to dissociate, monomers will become 
non-functional. This can be the case when synthetic peptides are 
of low affinity for the MHC. In order to test whether our assay can 
detect such suboptimal reagents, we artificially denatured MHC 
complexes by incubating them in a low pH buffer. We found that 
binding of W6/32, BB7.2, and B1.23.2 mAbs to acid-treated mon-
omers was considerably reduced, albeit not completely abolished 
(>90% reduction of MFI, Figure 3). At the same time, damaged 
monomers were revealed by an increased binding (>95% in MFI) 
of mAbs recognizing the free heavy chain, i.e., HCA2 (Figure 3) 
and HC10 (data not shown).
the Assay Can Report an Unsuccessful 
UV-Mediated Peptide-exchange on a 
Monomer
To test whether our assay can be used for assessing the quality 
of monomers produced by UV-exchange, we exposed mono-
mers containing a labile peptide to UV-light in the absence or 
presence of a replacement peptide. Without peptide addition, 
W6/32 binding was clearly decreased (MFI loss range: 34–64%) 
and HCA2 and HC10 mAb binding was induced as compared 
to no UV-treatment (Figure  4; Figure S3 in Supplementary 
Material). Residual binding of W6/32 to the beads might be due 
to incomplete dissociation of the monomers, as already observed 
(12). UV-exchange of the monomers in the presence of a relevant 
peptide prevented HCA2 and HC10 binding while it restored 
W6/32 binding for HLA-B*07 and -B*08. Note that the binding 
of W6/32 was not fully restored after addition of three different 
HLA-A*02 viral peptides, A*02-BRLF1 (Figure 4), A*02-CMV, 
and A*02-Flu (data not shown); BB7.2 mAb gave similar results 
for HLA-A*02 binding after UV-exchange (Figure S3B in 
Supplementary Material). Altogether, this suggests that the most 
reliable measure of an effective UV-exchange is the lack of binding 
of HC10 and HCA2, rather than the binding of the W6/32 mAb. 
Furthermore, only the multimers generated from monomers that 
FIGURe 4 | Quality control of UV-exchanged major 
histocompatibility complex (MhC) monomers. Monomers containing 
UV-labile peptides were left untreated or were exposed to UV-light in the 
presence or absence of a replacement peptide. Binding of the indicated 
anti-MHC monoclonal antibodies to these monomers was detected using 
a PE-labeled secondary antibody. Median fluorescence of the PE signal 
from two representative experiments out of three is plotted. Histograms of 
one of the experiments are shown in Figure S3A in Supplementary 
Material.
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were UV-exposed in the presence of a replacement peptide were 
able to stain antigen-specific cells within PBMCs (Figure S2 in 
Supplementary Material).
exemplary Application of the Assay
When PBMCs were tested with multimers that were generated 
from two frozen batches of HLA-A*02-MelanA monomers, 
we noticed that Batch 1 multimers did not stain any MelanA-
specific T cells while Batch 2 monomers did (Figure  5A). As 
a demonstration of how the assay is useful for controlling the 
quality of MHC monomers, we tested the two monomer batches 
with the bead assay. As shown in Figure 5B, W6/32 and BB7.2 
mAbs bound to Batch 2, but not Batch 1 monomers. This 
indicated that only Batch 2 monomers maintained an intact 
heterotrimeric MHC conformation. Batch 1 monomer also did 
not bind to HCA2 antibodies, suggesting a degradation of the 
MHC heavy chain as well. This was later confirmed by FPLC 
(data not shown). Hence, the assay can be used to control the 
integrity of monomers that have been stored at −80°C for longer 
periods.
dIsCUssIoN
Major histocompatibility complex monomers have revolution-
ized T cell immunology by allowing sensitive and robust detec-
tion of antigen-specific CD8+ T cells. Structural integrity of MHC 
monomers is crucial for their functionality and downstream 
applications. Therefore, quality control measures following 
production are essential. Although several tests exist to assess 
monomers, none of them really pinpoint their functionality 
in a quick, simple, and high-throughput manner. Testing the 
binding of MHC multimers on cells is by far the ultimate test; 
however, generating a cell bank of specific T cells is cumbersome 
and impractical for high-throughput screenings and epitope 
discovery purposes. Catering to the need for a cheap and quick 
way to report the integrity of monomers, we established a flow 
cytometry-based assay.
The two main applications of MHC monomers, i.e., fluores-
cent MHC multimers for flow cytometry analysis and artificial 
antigen presenting cells for T cell priming, use biotinylated 
forms of the MHC monomer. The principle of the assay is to 
load monomers on streptavidin-coated microspheres and 
subsequently label these beads using anti-MHC antibodies. 
This bead–monomer–antibody complex can then be detected 
on a flow cytometer with a fluorescent secondary antibody 
(Figure 1). Hence, both the biotinylation status and the func-
tional heterotrimeric conformation of a MHC monomer can be 
assessed.
To establish test conditions, we first determined optimal 
antibody and monomers concentrations to be used (both 
depend on the binding capacity of the beads, which might vary 
between batches). By using 0.05 µg/mL of monomers, we could 
clearly discriminate between biotinylated and non-biotinylated 
monomers (Figure  2). The assay can detect denaturation of 
MHC complexes by using a minimum combination of two 
anti-MHC antibodies, one that detects free heavy chains 
(HCA2 or HC10) and another that detects heterotrimeric MHC 
complexes (W6/32, BB7.2, or B1.23.2). This was demonstrated 
by denaturation of monomers with a brief acid treatment 
(Figure  3) or by UV-exposure without addition of a replace-
ment peptide (Figure  4). It is worth noting that, although it 
was described previously that HCA2 binds free HLA-A and 
HC10 binds free HLA-B and C chains (17–21), we observed 
that upon acid denaturation, HCA2 binds strongly to HLA-
A*02, HLA-B*07, and HLA-B*08 molecules, while HC10 reacts 
strongly with HLA-B*07 and -B*08 and very weakly with -A*02 
(Figure 4). Therefore, we recommend using a combination of 
several relevant anti-MHC antibodies to unambiguously moni-
tor monomers prepared with different HLA heavy chains using 
the conventional or the UV-exchange method, before they are 
FIGURe 5 | Application of the bead assay to test in-house produced major histocompatibility complex (MhC) monomers. Two batches of 
conventional HLA-A*02 monomers (Batch 1 and Batch 2), each generated with the Melan A peptide (ELAGIGLTV) were tested. (A) PBMCs from two HLA-A02(+) 
donors (indicated) were stained with APC-labeled MHC multimers generated from Batch 1 and PE-labeled MHC multimers generated from Batch 2. Multimer-
APC/PE vs. CD8 PE-Cy7 dot plots are shown. (B) Fluorescence histograms obtained in the bead test.
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used to generate MHC multimers or for other applications 
(Figure  5). Although we have demonstrated the feasibility of 
this assay using purified mAbs in combination with a secondary 
Ab, one may also use fluorescence-conjugated anti-HLA Abs 
(Figure S4 in Supplementary Material). Of note, the assay is not 
able to check for peptide identity, but can be complemented by 
determination of the peptide sequence using mass spectrometry 
(data not shown).
A clear advantage of this approach is the minimal amount of 
MHC monomer that is needed; by including appropriate isotype 
control stainings, we used 60  ng of monomer per experiment, 
which is far lower than what is generally required for SDS-PAGE 
analysis (10–20 µg) or for ELISA (approximately 300 ng). Another 
advantage is the ease of read-out via flow cytometry, which ena-
bles high-throughput quality assessment. The assay is quick and 
requires less than 2 h for sample preparation and less than 1 h for 
measurement and analysis, which is much shorter than the ELISA 
method which needs approximately 8 h (12). Additionally, in our 
hands, the ELISA method displays some intra-assay variability. 
Finally, the new assay is cost-effective and requires few reagents 
and specialized equipments. Although we described in this report 
a qualitative assessment of MHC monomers, it should also be 
feasible to quantify the amount of functional monomers by 
generating standard curves using reference MHC monomers of 
known concentrations. Altogether, we recommend this assay as a 
fast, robust, and affordable method to assess MHC monomers at 
the production step and upon long-term storage.
AUthoR CoNtRIBUtIoNs
PAC designed the experiments, analyzed the data, and wrote 
the manuscript. SH performed the experiments. HZ assisted 
the experiment design. BS-H provided blood samples. H-GR 
supervised the study. SP devised the concept of the assay. CG 
supervised the entire study and wrote the manuscript.
ACKNoWLedGMeNts
We thank Stefan Stevanović and his team for providing the syn-
thetic peptides and Claudia Falkenburger for antibody produc-
tion. We also thank Juliane Schneider for her critical evaluation 
of the written manuscript.
FUNdING
CG and PAC are supported by the Deutsche Forschungs-
gemeinschaft, SFB685 project Z05, H-GR by the DKTK, and 
the ERC grant (Mutaediting) and CG by the Wallace Coulter 
Foundation.
sUPPLeMeNtARY MAteRIAL
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.00096/full#supplementary-material.
8Chandran et al. Quality Control of MHC–Peptide Monomers
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 96
ReFeReNCes
1. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. 
Structure of the human class I histocompatibility antigen, HLA-A2. Nature 
(1987) 329:506–12. doi:10.1038/329506a0 
2. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific 
motifs revealed by sequencing of self-peptides eluted from MHC molecules. 
Nature (1991) 351:290–6. doi:10.1038/351290a0 
3. Matsui K, Boniface JJ, Reay PA, Schild H, Fazekas de St Groth B, Davis MM. 
Low affinity interaction of peptide-MHC complexes with T cell receptors. 
Science (1991) 254:1788–91. doi:10.1126/science.1763329 
4. Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, 
et  al. Validation of immunomonitoring methods for application in clinical 
studies: the HLA-peptide multimer staining assay. Cytometry B Clin Cytom 
(2016). doi:10.1002/cyto.b.21397 
5. Blanchfield JL, Shorter SK, Evavold BD. Monitoring the dynamics of T cell 
clonal diversity using recombinant peptide:MHC technology. Front Immunol 
(2013) 4:170. doi:10.3389/fimmu.2013.00170 
6. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK. 
Tricks with tetramers: how to get the most from multimeric peptide-MHC. 
Immunology (2009) 126:147–64. doi:10.1111/j.1365-2567.2008.02848.x 
7. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell 
JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 
274:94–6. doi:10.1126/science.274.5284.94 
8. Andersen RS, Kvistborg P, Frosig TM, Pedersen NW, Lyngaa R, Bakker AH, 
et al. Parallel detection of antigen-specific T cell responses by combinatorial 
encoding of MHC multimers. Nat Protoc (2012) 7:891–902. doi:10.1038/
nprot.2012.037 
9. Barnes E, Ward SM, Kasprowicz VO, Dusheiko G, Klenerman P, Lucas M. 
Ultra-sensitive class I tetramer analysis reveals previously undetectable 
populations of antiviral CD8+ T cells. Eur J Immunol (2004) 34:1570–7. 
doi:10.1002/eji.200424898 
10. Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhring HJ, et al. Cutting 
edge: predetermined avidity of human CD8 T cells expanded on calibrated 
MHC/anti-CD28-coated microspheres. J Immunol (2003) 171:4974–8. 
doi:10.4049/jimmunol.171.10.4974 
11. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding 
and crystallization of molecules expressed in Escherichia coli and complexed 
with single antigenic peptides. Proc Natl Acad Sci U S A (1992) 89:3429–33. 
doi:10.1073/pnas.89.8.3429 
12. Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher 
TN, et  al. Generation of peptide-MHC class I complexes through 
UV-mediated ligand exchange. Nat Protoc (2006) 1:1120–32. doi:10.1038/ 
nprot.2006.121 
13. Hadrup SR, Toebes M, Rodenko B, Bakker AH, Egan DA, Ovaa H, 
et  al. High-throughput T-cell epitope discovery through MHC peptide 
exchange. Methods Mol Biol (2009) 524:383–405. doi:10.1007/978-1-59745- 
450-6_28 
14. Parham P, Barnstable CJ, Bodmer WF. Use of a monoclonal antibody (W6/32) 
in structural studies of HLA-A,B,C, antigens. J Immunol (1979) 123:342–9. 
15. Parham P, Brodsky FM. Partial purification and some properties of BB7.2. 
A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant 
of HLA-A28. Hum Immunol (1981) 3:277–99. doi:10.1016/0198-8859(81) 
90065-3 
16. Rebai N, Malissen B. Structural and genetic analyses of HLA class I molecules 
using monoclonal xenoantibodies. Tissue Antigens (1983) 22:107–17. doi:10.1
111/j.1399-0039.1983.tb01176.x 
17. Hutter H, Hammer A, Blaschitz A, Hartmann M, Ebbesen P, Dohr G, 
et  al. Expression of HLA class I molecules in human first trimester and 
term placenta trophoblast. Cell Tissue Res (1996) 286:439–47. doi:10.1007/ 
s004410050713 
18. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 
2-microglobulin-free HLA class I heavy chain epitope mimicry by mono-
clonal antibody HC-10-specific peptide. J Immunol (2003) 171:1918–26. 
doi:10.4049/jimmunol.171.4.1918 
19. Seitz C, Uchanska-Ziegler B, Zank A, Ziegler A. The monoclonal antibody 
HCA2 recognises a broadly shared epitope on selected classical as well as 
several non-classical HLA class I molecules. Mol Immunol (1998) 35:819–27. 
doi:10.1016/S0161-5890(98)00077-7 
20. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured 
HLA-B locus heavy chains permit biochemical characterization of certain 
HLA-C locus products. J Immunol (1986) 137:2299–306. 
21. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-
B-specific monoclonal antibodies reactive with free heavy chains in western 
blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo- 
immuno-electron microscopy. Int Immunol (1990) 2:113–25. doi:10.1093/
intimm/2.2.113 
22. Peper JK, Schuster H, Loffler MW, Schmid-Horch B, Rammensee HG, 
Stevanovic S. An impedance-based cytotoxicity assay for real-time and 
label-free assessment of T-cell-mediated killing of adherent cells. J Immunol 
Methods (2014) 405:192–8. doi:10.1016/j.jim.2014.01.012 
23. Hadrup SR, Maurer D, Laske K, Frosig TM, Andersen SR, Britten CM, et al. 
Cryopreservation of MHC multimers: recommendations for quality assur-
ance in detection of antigen specific T cells. Cytometry A (2015) 87:37–48. 
doi:10.1002/cyto.a.22575 
24. Shi Y, Smith KD, Lutz CT. TAP-independent MHC class I peptide antigen 
presentation to alloreactive CTL is enhanced by target cell incubation at 
subphysiologic temperatures. J Immunol (1998) 160:4305–12. 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Chandran, Heidu, Zelba, Schmid-Horch, Rammensee, Pascolo 
and Gouttefangeas. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License (CC BY). The use, distribution or reproduc-
tion in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
